Search

Displaying results 4071 - 4080 of 8698 in total
  1. Drug

    Abciximab

    go.drugbank.com/drugs/DB00054
    ApprovedWithdrawn

    It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells. … Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules

    Categories: Glycoprotein IIb/IIIa Receptor-directed Monoclonal Antibodies
  2. Drug

    Ezatiostat

    go.drugbank.com/drugs/DB05460
    Investigational

    This medication is known to target Glutathione S-transferase P. Ezatiostat is a small molecule drug that is an analog inhibitor of glutathione S-transferase P1-1. … It might also be relevant as an adjunct therapy since a reduction in blood cell levels is also a common, toxic effect of many standard chemotherapeutic drugs.

  3. Drug

    Perflubutane

    go.drugbank.com/drugs/DB12821
    ApprovedWithdrawn

    It is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing; currently the leading procedure for detecting coronary heart disease.

  4. Drug

    Citicoline

    go.drugbank.com/drugs/DB12153
    ApprovedInvestigationalWithdrawn

    It has been investigated for the treatment, supportive care, and diagnosis of Mania, Stroke, Hypomania, Cocaine Abuse, and Bipolar Disorder, among others.

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  5. Drug

    Capreomycin

    go.drugbank.com/drugs/DB00314
    ApprovedInvestigational

    Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis
  6. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia

  7. Target

    Kainate receptors

    go.drugbank.com/bio_entities/BE0009793
    TargetHumans

    L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. … L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system (By similarity).

    Polypeptides: Glutamate receptor ionotropic, kainate 1, Glutamate receptor ionotropic, kainate 2Synonyms: Glutamate receptor 5, Glutamate receptor 6
  8. Drug

    Human interferon beta

    go.drugbank.com/drugs/DB14999
    ApprovedInvestigational

    It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity.[A191733,L12012] … [A191784] Interferon beta is currently being studied as a possible treatment for COVID-19, which results from infection with the novel 2019 SARS-CoV-2 virus.

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Desvenlafaxine

    go.drugbank.com/drugs/DB06700
    ApprovedInvestigational

    [A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD). … Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.

    Categories: Antidepressive Agents Indicated for Depression, Cytochrome P-450 Substrates
  10. Drug

    Vopratelimab

    go.drugbank.com/drugs/DB15378
    Investigational

    Vopratelimab is under investigation in clinical trial NCT02904226 (JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors).